Robert Chess - Sep 16, 2022 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)

Role
Director
Signature
Mark A. Wilson, Attorney-in-Fact
Stock symbol
NKTR
Transactions as of
Sep 16, 2022
Transactions value $
$0
Form type
4
Date filed
9/20/2022, 08:45 PM
Previous filing
Feb 10, 2022
Next filing
Sep 26, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NKTR Common Stock Award $0 +10.2K +4.57% $0.00 233K Sep 16, 2022 Direct F1, F2
holding NKTR Common Stock 2.1K Sep 16, 2022 by daughter F3
holding NKTR Common Stock 2.1K Sep 16, 2022 by son F3
holding NKTR Common Stock 2.1K Sep 16, 2022 by daughter F3
holding NKTR Common Stock 28.8K Sep 16, 2022 by Robert Chess Grantor Retained Annuity Trust
holding NKTR Common Stock 28K Sep 16, 2022 by Stacey Chess Grantor Retained Annuity Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NKTR Stock Option Award $0 +20.4K $0.00 20.4K Sep 16, 2022 Common Stock 20.4K $3.47 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.
F2 This RSU award vests in full, one year following September 16, 2022.
F3 The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose.
F4 This stock option vests in equal monthly installments over the one-year period beginning on September 16, 2022.